Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease.

ABSTRACT:

Background

Dysregulation of innate and adaptive immunity heralds both the development and progression of Parkinson's disease (PD). Deficits in innate immunity in PD are defined by impairments in monocyte activation, function, and pro-inflammatory secretory factors. Each influences disease pathobiology.

Methods and results

To define monocyte biomarkers associated with immune transformative therapy for PD, changes in gene and protein expression were evaluated before and during treatment with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim, Leukine^® ). Monocytes were recovered after leukapheresis and isolation by centrifugal elutriation, before and 2 and 6 months after initiation of treatment. Transcriptome and proteome biomar

SUBMITTER: Abdelmoaty MM 

PROVIDER: S-EPMC9270000 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature